Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Clinical effectiveness of Zavicefta® (ceftazidime avibactam) in severe Gram-negative infections

This promotional meeting is organised and funded by Pfizer and may include reference to Pfizer medicines relevant to agenda topics.

  • Bacterial Topic

Clinical effectiveness of Zavicefta® (ceftazidime avibactam) in severe Gram-negative infections

Date: 22nd September & 24th September

Time: 12pm - 22nd September 
            6pm - 24th September

Duration: 1 Hour

Additional details: This is a live webinar. A live Q&A with the speakers will be available. 

Register Here

About the webinar

This webinar is a promotional meeting that will focus on:
•    The risk factors for severe Gram-negative infections and carbapenem resistance
•    The importance of early adequate therapy in ICU 
•    A comparison of spectrum of activity of various agents, including Zavicefta (ceftazidime avibactam)
•    The importance of antimicrobial stewardship (AMS)

About the speakers

Professor Miguel Sánchez García
Director of Critical Care, 
Hospital Clinico San Carlos, Madrid

Dr Luke Moore
I
nfectious Diseases Consultant, 
Chelsea and Westminster Hospital NHS Foundation Trust, London

This meeting is organised & funded by Pfizer Ltd. Please note that, under the law and the ABPI Code of Practice, Pfizer may only promote its medicines and provide hospitality to members of the healthcare professions and other relevant decision makers. Therefore, no unqualified person (e.g. medical students, non-medical spouses/partners/family members) may be invited to or attend Pfizer promotional meetings.

 

Prescribing information

Zavicefta (ceftazidime avibactam)
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM. Basic NHS price: 10 vial pack £857.00.